What Researchers Did
Researchers retrospectively compared the effectiveness of two different doses (10 mg/mL vs. 24 mg/mL) of intratympanic dexamethasone in 37 adults with idiopathic sudden sensorineural hearing loss.
What They Found
Ten (53%) of 19 patients receiving 24 mg/mL dexamethasone showed a greater than 30-dB improvement in pure-tone average, significantly outperforming the 3 (17%) of 18 patients treated with 10 mg/mL (p = 0.0382). Earlier initiation of intratympanic dexamethasone treatment also significantly improved both pure-tone average and word recognition scores.
What This Means for Canadian Patients
Canadian patients with idiopathic sudden sensorineural hearing loss might benefit more from a higher dose (24 mg/mL) of intratympanic dexamethasone. Furthermore, seeking treatment as early as possible after symptom onset appears crucial for better hearing recovery outcomes.
Canadian Relevance
This study does not have a direct Canadian connection.
Study Limitations
This was a retrospective study with a small sample size, which limits the generalizability and strength of the findings.